Descartes-08

Cell therapy

Phase 3underway

Evidence outlook · registrational

Myasthenia Gravis: registrational readout pending

No completed mid-stage readout is on record. Registrational readout expected around 2026-12-30.

Also in development:Dermatomyositis · Phase 1/2

Development in Systemic Lupus Erythematosus stopped (2026-04-30) as a strategic decision by the sponsor. Source

Development in Multiple Myeloma stopped (2021-06) for reasons the sponsor has not stated. Source

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (1)
Myasthenia Gravis
Phase 2 (4)
Myasthenia Gravis
NCT04146051 · Cartesian Therapeutics
2019-12-04 – 2026-09-30 · Myasthenia Gravis, Generalized
What this study did
Other / comorbidity
NCT07391605 · Cartesian Therapeutics
2026-04-28 – 2028-05 · Antisynthetase Syndrome
What this study did
NCT06038474 · Cartesian Therapeutics
2024-02-12 – 2027-12-01 · Systemic Lupus Erythematosus (SLE)
What this study did
NCT04816526 · Cartesian Therapeutics
2021-12-01 – 2022-11-03 · Myeloma Multiple
What this study did
Phase 1/2 (1)
Myasthenia Gravis
Phase 1 (1)
Other / comorbidity
NCT03448978 · Cartesian Therapeutics
2018-03-08 – 2021-06-03 · Multiple Myeloma
What this study did

Competitive landscape

This drug's own stage for Dermatomyositis: Phase 1/2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Descartes-08: this drugPhase 1/2Cell therapyBCMA (B-cell maturation antigen)not yet gradedNo reviewed efficacy summary in this indication
Brepocitinib (Lisraya)ApprovedSmall moleculeTYK2/JAK1not yet gradedNo reviewed efficacy summary in this indication
Repository Corticotropin (Acthar Gel)ApprovedPeptideMelanocortin receptors (primarily MC2R on the adrenal cortex), Melanocortin 2 receptor (MC2R) (agonist)not yet gradedNo reviewed efficacy summary in this indication
PF-06823859Phase 3Monoclonal antibodyInterferon beta (IFN-beta)not yet gradedNo reviewed efficacy summary in this indication
CadefrecitinibDiscontinuedSmall moleculeTYK2not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(4 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Descartes-08 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (2)
December 2026 (2)
Phase 2Systemic Lupus Erythematosus (SLE)Active not recruiting
Est. primary completion 2026-12-01 · NCT06038474 · CT.gov ↗
What to watch
Phase 3Myasthenia GravisActive not recruiting
Est. primary completion 2026-12-30 · NCT06799247 · CT.gov ↗
What to watch
2027 (2)
November 2027 (1)
Phase 2Antisynthetase SyndromeRecruiting
Est. primary completion 2027-11 · NCT07391605 · CT.gov ↗
What to watch
December 2027 (1)
Phase 1/2Myasthenia GravisRecruiting
Est. primary completion 2027-12 · NCT07089121 · CT.gov ↗
What to watch

See the full readout calendar ↗